APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Price, Forecast & Analysis
Canada - TSX:APLI - CA03783R1073 - Common Stock
APLI.CA Key Statistics, Chart & Performance
The current stock price of APLI.CA is 0.02 CAD. In the past month the price decreased by -33.33%. In the past year, price decreased by -42.86%.
APLI.CA Latest News, Press Relases and Analysis
APLI.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.61 | 3.19B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.61B | ||
| CRON.CA | CRONOS GROUP INC | 24.29 | 1.30B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.35 | 879.73M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.26 | 623.65M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | 122.6 | 611.04M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 497.23M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 340.31M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 20.6 | 339.03M | ||
| HITI.CA | HIGH TIDE INC | N/A | 321.01M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 284.78M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 242.25M |
Related stock screener links
About APLI.CA
Company Profile
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Company Info
APPILI THERAPEUTICS INC-CL A
#21-1344 Summer Street
Halifax NOVA SCOTIA B3H 0A8 CA
CEO: Armand Balboni
Employees: 7
Phone: 19024424655
APPILI THERAPEUTICS INC-CL A / APLI.CA FAQ
What does APPILI THERAPEUTICS INC-CL A do?
Appili Therapeutics, Inc. operates as a biopharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Can you provide the latest stock price for APPILI THERAPEUTICS INC-CL A?
The current stock price of APLI.CA is 0.02 CAD. The price decreased by -20% in the last trading session.
Does APPILI THERAPEUTICS INC-CL A pay dividends?
APLI.CA does not pay a dividend.
How is the ChartMill rating for APPILI THERAPEUTICS INC-CL A?
APLI.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of APLI stock?
APPILI THERAPEUTICS INC-CL A (APLI.CA) operates in the Health Care sector and the Pharmaceuticals industry.
What is APPILI THERAPEUTICS INC-CL A worth?
APPILI THERAPEUTICS INC-CL A (APLI.CA) has a market capitalization of 2.43M CAD. This makes APLI.CA a Nano Cap stock.
APLI.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to APLI.CA. When comparing the yearly performance of all stocks, APLI.CA is a bad performer in the overall market: 80.67% of all stocks are doing better.
APLI.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APLI.CA. Both the profitability and financial health of APLI.CA have multiple concerns.
APLI.CA Financial Highlights
Over the last trailing twelve months APLI.CA reported a non-GAAP Earnings per Share(EPS) of -0.08. The EPS increased by 80% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |